← Eichor
Condition: Relapsed Refractory Small Cell Lung Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsed Refractory Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
Phase 1 · 1 location(s) · Sichuan University · NCT06348797Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
Phase 2 · 1 location(s) · Diwakar Davar · NCT05669846A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
Phase 1 · 3 location(s) · Shanghai Jiao Tong University School of Medicine · NCT02889666A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in
Phase 1/Phase 2 · 7 location(s) · Hummingbird Bioscience · NCT06956690A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relaps
Phase 1/Phase 2 · 12 location(s) · Bristol-Myers Squibb · NCT07325136A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular
Phase 1 · 83 location(s) · Pfizer · NCT03460977177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Radiopharm Theranostics, Ltd · NCT07189871Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480213DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroen
Phase 2 · 59 location(s) · Boehringer Ingelheim · NCT05882058TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
EARLY_Phase 1 · 1 location(s) · TCRCure Biopharma Ltd. · NCT07246304Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Phase 1/Phase 2 · 11 location(s) · Chipscreen Biosciences, Ltd. · NCT05271292TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
Phase 1 · 1 location(s) · Shenzhen TargetRx Co., Ltd. · NCT06484816A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants Wit
Phase 1/Phase 2 · 48 location(s) · Merck Sharp & Dohme LLC · NCT06780137This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of
Phase 1 · 2 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07249879Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
Phase 1 · 1 location(s) · SciTech Development, Inc. · NCT06922539
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.